TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Remimazolam and Dexmedetomidine for Intraoperative Sedation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient scheduled for lower extremity surgery under regional anesthesia, aged 19-70, of ASA class I or II.~Exclusion Criteria:~* Patient refusal~* Contraindications to regional or neuraxial anesthesia (patient refusal, increased intracranial pressure, infection at puncture site, underlying neurologic disease, severe hypovolemia, aortic or mitral stenosis, thrombocytopenia or coagulopathy)~* Contraindications to dexmedetomidine or remimazolam administration~* Allergy to dexmedetomidine or remimazolam~* Baseline MOAA/S score of 4 or less~* Pregnancy~* Other conditions considered unsuitable by the investigators

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Remimazolam (Type: ACTIVE_COMPARATOR): None
- Dexmedetomidine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* History (Hx) of chronic systolic heart failure of ischemic or non-ischemic etiology of at least 4 weeks duration; Currently, New York Heart Association (NYHA) functional Class II and on optimal dose, or maximally tolerated dose of standard heart failure medicines (advisable to include ACE-I/ARBs; beta-blockers) and diuretics if indicated for fluid overload. Should have participated in the double-blind phase of the EMPHASIS-HF trial~Exclusion Criteria:~* Severe chronic systolic heart failure symptomatic at rest despite optimal medical therapy; estimated glomerular filtration rate (eGFR) \<30 ml/min/1.73m2.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eplerenone arm (Type: ACTIVE_COMPARATOR): Eplerenone administered on top of background standard heart failure therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female adults aged \> 40 years with a diagnosis of COPD~* Current smokers or ex-smokers~* A post-bronchodilator FEV1 \< 50% of the predicted normal value and a post-bronchodilator FEV1/FVC ratio \< 0.7 at least 10-15 minutes after 4 puffs (4 x 100 µg) of salbutamol pMDI~* At least one exacerbation in the 12 months preceding the screening visit~Exclusion Criteria:~* Pregnant or lactating women~* Diagnosis of asthma, history of allergic rhinitis or atopy~* Patients treated for exacerbations in the 4 weeks prior to screening visit~* Patients treated with non-cardioselective ß-blockers in the month preceding the screening visit~* Patients treated with long-acting antihistamines unless taken at stable regimen at least 2 months prior to screening and to be maintained constant during the study or if taken as Pro Re Nata~* Patients requiring long term ( at least 12 hours daily) oxygen therapy for chronic hypoxemia~* Known respiratory disorders other than COPD~* Patients who have clinically significant cardiovascular condition

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CHF 5993 100/6/12.5 µg (Type: EXPERIMENTAL): Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose (BDP/FF/GB) (Beclometasone dipropionate / Formoterol Fumarate / glycoppyronium Bromide)
- Symbicort Turbuhaler 160/4.5 µg (Type: ACTIVE_COMPARATOR): Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (160µg + 4.5 µg expresses the delivered dose; 200 µg + 6 µg expresses the metered dose) ( BUD/FF) (Budesonide/Formoterol Fumarate)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Participant is male or female 18 years of age or older~2. Participant has received at least one dose of an ABT-493- and/or ABT- 530 containing regimen in a prior AbbVie hepatitis C virus (HCV) Phase 2 or 3 study~3. The interval between the last dose of the AbbVie direct-acting antiviral agent (DAA) therapy from the previous clinical study and enrollment in Study M13-576 must be no longer than 2 years for subjects who have not been retreated. Participants who have been treated with a commercially available anti-HCV treatment may be enrolled greater than 2 years after the last dose of the AbbVie DAA therapy from the previous clinical study.~4. Participant must voluntarily sign and date the informed consent form approved by an Independent Review Board or Ethics Committee prior to the initiation of any study-specific procedures.~5. Participant completed the post-treatment period of an eligible prior study.~Exclusion Criteria:~1. The investigator considers the participant unsuitable for the study for any reasons (e.g., failure to comply with study procedures in the prior AbbVie clinical study).~2. Receipt of any investigational HCV antiviral treatment after receiving ABT-493 and/or ABT-530 in the prior study.~3. Participants who experienced non-virologic treatment failure due to premature discontinuation of study drug in prior study of ABT-493/ABT-530.~4. Participation in AbbVie's Study M15-942 protocol for re-treatment for virologic failure in the prior Phase 2 or 3 study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HCV-infected Participants (Type: NO_INTERVENTION): Hepatitis C virus (HCV)-infected participants who received ABT-493 and/or ABT-530 in prior Phase 2 or 3 clinical studies with these agents for the treatment of chronic HCV and were not retreated prior to entering this study. No AbbVie study drug was administered in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of complicated lower urinary tract infection or pyelonephritis~Exclusion Criteria:~* Women who are pregnant, nursing or of child-bearing potential and not using a medically accepted, effective method of birth control~* History of moderate or severe hypersensitivity reactions to antibiotic medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Resynchronization Therapy Efficacy Enhancements

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is willing to sign and date the study patient Informed Consent form.~* Subject is at least 18 years of age (or older, if required by local law).~* Subject is expected to remain available after enrollment to complete follow-up visits in both arms of the study~* Subject has had a Medtronic Viva or Brava CRT-D device implanted at least 30 days prior to enrollment.~* Subject has history of AF burden, of at least 6 days of at least 4 hours of AF over any 4 week period within the last 90 days as documented in device diagnostic data OR if subject has no atrial lead (therefore no device diagnostic data) but clinical evidence of high AF burden.~* Subject has demonstrated history of being able to complete Left Ventricular Capture Management (LVCM) documented in device data.~* Subject has a documented % V pacing during AF of less than or equal to 97% within 90 days prior to enrollment or within 10 days after enrollment.~Exclusion Criteria:~* Subject has undergone AV node ablation for treatment of AF.~* Subject has complete or 3rd degree AV block.~* Subject has had an MI within 30 days.~* Subject has medical conditions that limit study participation (per physician discretion).~* Subject is enrolled in one or more concurrent studies that could confound the study results as determined by Medtronic.~* Subject has a limited life expectancy for non-cardiac causes that would not allow completion of the study.~* Subject is pregnant (in the US, all women of child-bearing potential must undergo a pregnancy test within seven days prior to CRTee download).~* Subject meets the exclusion criteria required by local law.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A: CAFR first (Type: OTHER): Subjects randomized to Group A will receive CAFR first, then cross over to CAFRPlus.
- Group B: CAFRPlus first (Type: OTHER): Subjects randomized to Group B will receive CAFRPlus first, then cross over to CAFR.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- Patients who meet ALL the following criteria can be enrolled:~* Male or female aged at least 18 years,~* With a diagnosis of active Psoriatic Arthritis (PsA),~* For whom the treating physician has made the decision to commence apremilast treatment in accordance with the local label and reimbursement criteria (refer to the reimbursement conditions mentioned in Section 1.2),~* Able to follow the instructions of the study,~* Having signed an Informed Consent Form (ICF).~Exclusion Criteria:~- Patients who meet AT LEAST one of the following exclusion criteria will be excluded:~* Women who are pregnant, breastfeeding or planning on becoming pregnant,~* Non-menopausal women who are not using an adequate contraception method,~* Patients with hypersensitivity to apremilast or to one of its excipients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Use of apremilast in patients with active PsA (Type: None): Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion criteria:~1. Healthy male and female subjects~Exclusion criteria:~1. Any relevant deviation from healthy conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 Empagliflozin/Metformin (T) (Type: EXPERIMENTAL): fixed-dose-combination tablet, oral with 240 ml water under fasted conditions
- 2 Empagliflozin/Metformin (T) (Type: EXPERIMENTAL): fixed-dose-combination tablet, oral with 240 ml water under fed conditions
- 3 Empagliflozin + Metformin (R) (Type: EXPERIMENTAL): tablets, oral with 240 ml water under fasted conditions
- 4 Empagliflozin + Metformin (R) (Type: EXPERIMENTAL): tablets, oral with 240 ml water under fed conditions
- 5 Empagliflozin/Metformin (T) (Type: EXPERIMENTAL): fixed-dose-combination tablet, oral with 240 ml water under fed conditions
- 6 Empagliflozin + Metformin (R) (Type: EXPERIMENTAL): tablets, oral with 240 ml water under fed conditions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Currently admitted to a NICU or ICU at a participating site 2. Chronological age less than 24 months 3. Evidence of colonization with SA (MRSA or MSSA) based on a positive nasal surveillance culture. Randomization must occur within 7 days (168 hours) of when the site's laboratory reports the first SA positive nasal surveillance swab 4. The attending neonatologist/ intensivist anticipates that the infant will remain in the ICU for a minimum of 14 days after enrollment 5. Parent or legal guardian agrees that the infant will not participate in a research trial involving the administration of an investigational drug for 14 days following enrollment~Exclusion Criteria:~1. Receipt of an investigational drug as part of a research trial within the past 14 days 2. Previously enrolled and participated in this trial 3. Has an active or previous SA infection 4. Currently receiving topical or intranasal mupirocin 5. Has a rash in an area to which mupirocin will be directly applied 6. Has any of the following congenital abnormalities: --A congenital skin disorder (i.e. - epidermolysis bullosa, icthyosis) --An opened neural tube defect --Confirmed or suspected choanal atresia --Any of the following abdominal wall defects: wound dehiscence, gastroschisis, open abdominal wound (small abdominal wall defects such as ostomy sites or peritoneal drain sites are not exclusionary) 7. Is nasally intubated 8. Known hypersensitivity to the trial product or its constituents 9. Known or suspected immune deficiency. Infants born to HIV-seropositive mothers with the following risk factors for intrapartum transmission will not be eligible to participate: --Mother's most recent viral load within the past 3 months was \> 1,000 copies/ml or --Mother's viral load is not known or has has not been measured in the past 3 months. 10. Any other condition(s) that in the opinion of the investigator would jeopardize the safety or rights of a participant or would render the participant unable to comply with the protocol

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Months
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Subjects receive a 5-day course of mupirocin calcium ointment 2 % 20 mg intranasally applied every 8 hours and a topical skin application (umbilical and perianal area) of mupirocin calcium cream 2% 20 mg applied every 8 hours for a total of 15 doses
- Group 2 (Type: NO_INTERVENTION): No treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Auricular Acupressure for Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult female patients aged above 18 years old;~* A diagnosis of breast cancer stage I-III;~* Chemotherapy- naive;~* Auricular therapy-naive;~* Be able to communicate in Chinese mandarin;~* Have at least completed a primary school education;~* Agree to participate in the study and be willing to give written informed consent;~* Be scheduled to receive the first cycle of chemotherapy with moderately-high to highly emetogenic potentials;~* Be provided with standard antiemetic medications during chemotherapy.~Exclusion Criteria:~* Extremely weak, disabled or immunocompromised cancer patients;~* Be unable to follow the study instructions to do AT intervention or other research procedures;~* Have concurrent radiotherapy or other kinds of antineoplastic therapy;~* Currently take part in clinical studies on anti-emetic medications or other kinds of non-pharmacological interventions to control CINV, or other studies which are believed to produce potential interactions with this AT trial;~* Have other health problems which may affect the symptoms of CINV such as gastrointestinal disease, liver disease, migraine, tinnitus and Ménière's disease, etc.;~* Ear skin problems which are not appropriate for auricular acupressure including ear infections, ear scars and rashes, ear frostbite, and ear abscess, etc.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- True Auricular Acupressure Group (Type: EXPERIMENTAL): Participants in this group will receive standard antiemetics before and during chemotherapy, and a 5-day auricular acupressure treatment protocol for controlling nausea and vomiting during the first cycle of chemotherapy.
- Sham Auricular Acupressure Group (Type: SHAM_COMPARATOR): Participants in this group will receive standard antiemetic medications before and during chemotherapy, and a 5-day sham auricular acupressure intervention protocol during the first cycle of chemotherapy.
- Standard Care Group (Type: OTHER): Participants in this group will only receive standard anti-emetic treatment before and during chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* No fever on day of vaccination~* History of varicella or residence in a VZV-endemic area for ≥30 years~* Females of reproductive potential must have a negative pregnancy test and must agree to use acceptable methods of birth control~Exclusion Criteria:~* History of hypersensitivity reaction to any vaccine component~* Prior receipt of any varicella or zoster vaccine~* Prior history of herpes zoster~* Have recently had another vaccination~* Pregnant or breastfeeding~* Use of immunosuppressive therapy~* Known or suspected immune dysfunction~* Concomitant antiviral therapy

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ZOSTAVAX™ (AMP) (Type: EXPERIMENTAL): ZOSTAVAX™ manufactured with an alternative process
- ZOSTAVAX™ (Type: ACTIVE_COMPARATOR): ZOSTAVAX™ manufactured with the current process

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or females 18 years of age or older~* opioid naïve~* Have an initial pain intensity score of at least 50 mm VAS~* In good health as determined by the investigator on the basis of medical history and physical examination~* Have moderate to severe chronic non-neuropathic LBP that has been present daily for at least several hours per day for a minimum of three months prior to the Screening~* Any adjunct therapy for back pain such as physical therapy, biofeedback therapy, acupuncture therapy or herbal remedies, based on the patient's current status should remain unchanged during the period of participation of the patient~* Written informed consent~Exclusion Criteria:~* Pregnant and/or lactating~* Radiculopathy, fibromyalgia, reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), acute spinal cord compression, cauda equina compression, acute nerve root compression, severe lower extremity weakness or numbness, bowel or bladder dysfunction secondary to cauda equina compression, diabetic amyotrophy, meningitis, discitis, or back pain due to secondary infection or tumor~* Cannot or will not agree to stop local regional pain treatments during the study (nerve/plexus blocks or ablation, neurosurgical procedures for pain control, or inhalation analgesia). The patient must not have a nerve/plexus block within 4 weeks of screening~* Intend to alter physical therapy regimen during the study.~* Surgical procedures directed towards the source of back pain within 6 months of screening~* Pain which is secondary to confirmed or suspected neoplasm~* Dysphagia or difficulty swallowing tablets or capsules, or an inability to take oral medication~* Significant prior history of substance abuse or alcohol abuse~* Use of any investigational medication within 30 days prior to the first dose of study medication~* Previous exposure to oxymorphone~* History of clinically significant intolerance to oxymorphone or a known hypersensitivity to opioid analgesics~* History of seizure~* Ileostomy or colostomy~* Use of MAO inhibitor within 14 days prior to the start of study medication~* Other clinically significant conditions as judged by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete